GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - RHYTHM PHARMACEUTICALS INC

Financial Performance:

• Secured a $750 million debt facility, with only $250 million currently drawn down, demonstrating a strategic move to leverage debt while maintaining shareholder-friendly dilution sensitivity.
• Announced an amendment to the LG Chem agreement involving a "buy-down" of royalties, reflecting increased confidence in the commercial viability of Bivomeragon, particularly for Hypothalamic Obesity (HO).
• Current commercial metrics for Bivomeragon (Bivomelagon) show 700 acquired patient start forms since the March 19th launch, with no observed slowdown entering Q4.
• Revenue recognition is anticipated to expand as international markets, specifically Germany and Japan, progress through regulatory and reimbursement hurdles.

Guidance and Future Outlook:

• Management expects the "modest" growth phase in Japan to last 12 months due to regulatory two-week prescription limits, after which full prescribing freedom is expected.
• Anticipates initiating a new HO trial with Vivomelagon imminently and a Prader-Willi Syndrome (PWS) trial by mid-year/early Q3 2027.
• Long-term growth strategy includes a dual-formulation approach (daily oral and weekly Rhythm 718) for major indications like HO and PWS, while selecting single formulations for smaller indications.
• Forecasts continued organic growth for rare disease indications over decades rather than a traditional "zero-to-peak" trajectory, citing examples like Gaucher disease.

Business Segments and Product Lines:

• Bivomeragon (Bivomelagon): Commercially launched for Bardet-Biedl Syndrome (BBS) and Hypothalamic Obesity (HO); the HO launch is described as steady and successful with consistent patient enrollment.
• Vivomelagon (Rhythm 718): Pipeline molecule intended for combination therapy and specific indications; new HO trials are planned to evaluate this weekly formulation.
• Prader-Willi Syndrome (PWS): Early-stage data from a 6-month open-label study at the University of Florida showed consistent BMI loss, favorable DEXA scan results (fat vs. lean loss), and improvements in anxiety/distress scores.
• MC4R Agonism Platform: Core strategic focus on expanding the MC4R pathway utility beyond genetic obesity to acquired conditions like HO and complex genetic syndromes like PWS.

Market and Competitive Landscape:

• Hypothalamic Obesity (HO): Estimated potential patient population has grown from a pre-launch figure of 2,000+ suspected/diagnosed cases to a confidence range of 5,000–10,000 globally; diagnosis remains a primary bottleneck as the condition is historically under-recognized in endocrinology.
• International Expansion: Aggressive "pay-as-you-go" market entry strategy; Germany is the next priority (requiring GBA exception for non-lifestyle medication classification); Japan has a population incidence potentially larger than the US, supported by a 50+ person local team.
• Competition: Differentiates from GLP-1 agonists by targeting the satiety pathway (MC4R) rather than creating a "starvation state," aiming to preserve lean mass while reducing fat.

Risks and Challenges:

• Regulatory Barriers: Significant hurdles in international reimbursement, such as Germany classifying obesity drugs as "lifestyle medications" and Japan's initial two-week prescription safety constraints.
• Diagnostic Delays: In HO, a large majority of patients remain in the "suspected" category, requiring active identification by medical science liaisons to convert to diagnosed cases.
• Complexity of PWS: The disease involves obsessive-compulsive behaviors where patients may still seek snacks despite biological satiety signals, creating "noise" in clinical data and adherence challenges.
• Rare Disease Dynamics: Market size estimates are inherently "softer" and subject to revision as the company gains more global field data and confirms prevalent vs. incident populations.

Management Commentary and Tone:

• CEO David Meeker maintained a confident and strategic tone, emphasizing the "profound" and "consistent" nature of results in HO trials despite initial skepticism regarding hypothalamic injury.
• Management dismissed media rumors and focused strictly on business execution, expressing strong satisfaction with current commercial momentum and the LG Chem deal structure.
• Emphasized a "science-driven" portfolio approach, removing incentives that previously favored specific products over others.

Analyst Questions and Answers:

• LG Chem Deal Structure: Confirmed the royalty buy-down was based on consensus estimates, aligning both parties on value and removing "incremental royalty" penalties for new indications.
• HO Market Size: Clarified that the 2,000+ pre-launch number has grown significantly; while exact updates are withheld during launch to avoid "soft number" confusion, the 5,000–10,000 global range is considered robust.
• PWS Data Interpretation: Clarified that 6-month data showed consistent results across BMI, DEXA, and behavioral metrics, with a 52-week data readout expected in Spring 2027.
• Daily vs. Weekly Formulation: Explained that for PWS, experts (e.g., Dr. Miller) prefer the daily oral dose to align with the patient population's need for routine and to manage obsessive-compulsive snacking behaviors.
• 2027 Catalysts: Highlighted that 2027 will be heavy on trial initiations (HO, PWS) and combination strategy updates rather than near-term readouts.

Other Key Points:

• Discussed the physiological mechanism of MC4R agonism restoring a "normal" satiety signal rather than inducing aversion to food, which is critical for PWS patients with complex behavioral drivers.
• Noted that the company is moving beyond the initial genetic obesity focus to treat acquired hypothalamic damage and complex multi-gene syndromes.
• Mentioned specific international challenges, such as the "two-week safety dynamic" in Japan designed to prevent rapid, unmonitored adoption of new therapies.